Navigation Links
NovaBay Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results
Date:8/14/2009

EMERYVILLE, Calif., Aug. 14 /PRNewswire-FirstCall/ -- NovaBay((R)) Pharmaceuticals, Inc. (NYSE Amex: NBY), a clinical stage biopharmaceutical company developing first-in-class anti-infective products for the treatment and prevention of a wide range of infections without causing resistance, reported today its financial results and operational highlights for the second quarter of 2009 ended June 30, 2009.

License and collaboration revenue for the second quarter of 2009 increased $ 0.9 million to $2.3 million from $1.4 million for the second quarter of 2008. This revenue consisted almost exclusively of amounts earned under the license and collaboration agreements with Alcon (NYSE: ACL), and beginning with this quarter, Galderma S.A., for amortization of the upfront technology access fees, receipt of milestone payments, and other amounts that have been reimbursed for the funding of research and development activities performed during the period.

The net loss for the second quarter of 2009 was $0.3 million, or $0.01 per share, compared to a net loss of $2.4 million, or $0.11 per share, reported for the second quarter of 2008. As of June 30, 2009, the company's cash, cash equivalents and short-term investments totaled $10.7 million, a net decrease of only $1.4 million from the $12.1 million reported at December 31, 2008. This represents a 75% reduction from the $5.5 million decrease during the first six months of 2008. The decreased burn rate in 2009 was largely due to cost containment measures, delayed research, development, and clinical expenses and receipt of a milestone and higher reimbursement payments from Alcon and upfront payments fr
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NovaBay(R) Pharmaceuticals Names Roy J. Wu as Senior Vice President for Business Development
2. NovaBay(R) Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
3. NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
4. NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBays Novel Aganocide Drugs for Major Dermatological Conditions
5. NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock
6. Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
7. Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT
8. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
9. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
11. Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Freeslate, Inc ., the ... that Lupin Limited, one of India’s top five pharmaceutical ... PharmD System for high throughput solid form screening. ... on a wide range of quality, affordable generic and ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, ... the Russian Federation , ... Independent States (CIS). Nemonoxacin is a novel antibiotic for the ...
(Date:1/14/2014)... DC (PRWEB) January 14, 2014 Carahsoft ... for Thursday, January 23, 2014 at 2pm EST (11am ... Knowledge.” The topic focuses on how technology can turn ... critical decisions for government agencies. The online webinar will ...
(Date:1/14/2014)...  3D Communications, a leading provider of strategic communications services to corporations ... in the United States and ... , JD, is returning to the firm,s Washington, D.C. ... after more than two years of service as Associate Commissioner for ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2
... Recently, academic debate has been swirling around the existence ... of phenomena, including photosynthesis, the process by which organisms ... suggested that entanglement (the quantum interconnection of two or ... separated in physical space) could be occurring in the ...
... Aug. 6 Rashid Chotani , M.D., ... Programs.  In this role, Chotani will lead chemical and biological programs that ... of the Secretary of Defense, as well as civilian agencies such as ... Disease Control. , , , ...
... 5, 2010 at 4:30 p.m. Eastern Time , ... BOTHELL, WA and VANCOUVER , Aug. 5 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, ... results for the three and six months ended June 30, 2010 and reviewed the ... , The Company ...
Cached Biology Technology:TASC, Inc. Appoints Rashid Chotani to Lead Chemical-Biological Defense Programs 2TASC, Inc. Appoints Rashid Chotani to Lead Chemical-Biological Defense Programs 3OncoGenex Reports Second Quarter Financial Results 2OncoGenex Reports Second Quarter Financial Results 3OncoGenex Reports Second Quarter Financial Results 4OncoGenex Reports Second Quarter Financial Results 5OncoGenex Reports Second Quarter Financial Results 6OncoGenex Reports Second Quarter Financial Results 7OncoGenex Reports Second Quarter Financial Results 8OncoGenex Reports Second Quarter Financial Results 9
(Date:7/9/2014)... to switch out one gene for another in a ... science fiction to reality within this decade. As with ... hope of fixing disease-causing genes in humans, for example--as ... have put one of those concerns to rest: using ... occurrence of mutations in the cells. The new results ...
(Date:7/9/2014)... LAFAYETTE, Ind. - Regulated deer hunts in Indiana state ... from decades of damage caused by overabundant populations of ... team led by Michael Jenkins, associate professor of forest ... Resources policy of organizing hunts in state parks has ... and wildflowers rendered scarce by browsing deer. , ...
(Date:7/9/2014)... from the Spanish National Cancer Research Centre (CNIO) have ... cells, also regulates cell division in stratified epitheliathose that ... cover the oesophagus or the vaginain adult organisms. According ... journal Nature Communications , this factor could also ... from stratified epithelia of the oesophagus and skin. , ...
Breaking Biology News(10 mins):No extra mutations in modified stem cells, study finds 2No extra mutations in modified stem cells, study finds 3Hunting gives deer-damaged forests in state parks a shot at recovery 2CNIO scientists discover that pluripotency factor NANOG is also active in adult organisms 2
... serendipity, researchers at North Carolina State University have found ... of intestinal birth defects may also inhibit the growth ... of chemical compounds created by NC State chemist Dr. ... of particular interest to her research: a compound that ...
... Indonesia has promised to become a world leader ... committed to a 26% reduction in greenhouse gas emissions ... 14% would have to come from reducing emissions from ... and other bodies are expected to raise total emission ...
... global framework for the safe production and use of ... Australia. The South-Pacific plant has been traditionally used ... some countries. Leading world Kava experts Dr Jerome ... Teschke from Wolfgang Goethe-University, Frankfurt, Germany; and Dr Vincent ...
Cached Biology News:Compound useful for studying birth defects may also have anti-tumor properties 2Hotspots of carbon confusion in Indonesia threaten to warm the world more quickly 2Hotspots of carbon confusion in Indonesia threaten to warm the world more quickly 3Hotspots of carbon confusion in Indonesia threaten to warm the world more quickly 4Hotspots of carbon confusion in Indonesia threaten to warm the world more quickly 5Experts propose global guidelines for safe use of Kava and new Australian study 2
TUP1 Market Segment: Molecular Biology...
In plasmid or lambda vector. Please inquire for more details!...
Goat polyclonal to Sarcosine Oxidase (HRP) ( Abpromise for all tested applications). Antigen: Full length protein: Sarcosine Oxidase (microbial). Entrez Gene ID: 51268 Swiss Protein ID: ...
... polyclonal to SARA ( Abpromise for ... Synthetic peptide: PVPKEMEQPV QTEEEDVELP conjugated to ... Fruit fly (Drosophila melanogaster) SARA. Conserved ... Entrez Gene ID: 9372 ...
Biology Products: